MAPT and Parkinson disease: When the effects of recalculated GRS-AD after excluding the APOE region on longitudinal CSF biomarkers were investigated, the effects were the same as those of the original GRS-AD, except that the recalculated GRS-AD was no longer associated with CSF αSyn levels in PD patients and CSF p-tau/Aβ42 levels in HC subjects (Supplementary Table 3).